Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 1 - Drugs for disorders of the alimentary tract or the digestive system
Patents for A61P 1 - Drugs for disorders of the alimentary tract or the digestive system (125,798)
08/2003
08/05/2003US6602984 Human elastase IV
08/05/2003US6602881 Anti-inflammatory uses of manzamines
08/05/2003US6602874 5-(2-(4-methylpiperazin-1-yl)-phenyl)- furan-2-carboxylic acid 4-chlorobenzylamide, for example; treating or preventing migraine, depression and other disorders for which a 5-HT1, agonist or antagonist is indicated
08/05/2003US6602872 Substituted pyridazines having cytokine inhibitory activity
08/05/2003US6602667 Of given sequence; useful for diagnosis, prognosis, treatment of inflammatory disorders; screening to identify ligands which bind the polynucleotides
08/05/2003US6602525 Compositions comprising nitrofurantoin and uva ursi
08/05/2003CA2275595C Prevention and treatment of skeletal disorder with ep2 receptor subtype selective prostaglandin e2 agonists
08/05/2003CA2087672C 1,5-benzodiazepine derivatives
08/05/2003CA2079374C (bicyclic-azaarylmethoxy)indoles as inhibitors of leukotriene biosynthesis
08/01/2003CA2370396A1 Hepatitis c inhibitor tri-peptides
08/01/2003CA2369970A1 Hepatitis c inhibitor tri-peptides
07/2003
07/31/2003WO2003062426A1 Novel protein, its dna and use thereof
07/31/2003WO2003062390A2 Compositions and methods for the modulation of sphingolipid metabolism and/or signaling
07/31/2003WO2003062278A1 MONOCLONAL ANTIBODIES AGAINST EXTRACELLULAR LOOPS OF C5aR
07/31/2003WO2003062275A1 Glycoisoforms of adiponectin and uses thereof
07/31/2003WO2003062274A1 Novel proteins and dnas thereof
07/31/2003WO2003062265A2 Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
07/31/2003WO2003062252A1 Edg receptor agonists
07/31/2003WO2003062248A2 N-(benzyl)aminoalkylcarboxylates, phosphinates, phosphonates and tetrazoles as edg receptor agonists
07/31/2003WO2003062245A1 Fused bicyclic pyrimidine derivatives
07/31/2003WO2003062241A1 Fused heterocyclic succinimidecompounds and analogs thereof, modulators of nuclear hormone receptor function
07/31/2003WO2003062228A1 Proline compounds as ns3-serine protease inhibitors for use in treatment of hepatites c virus infection
07/31/2003WO2003062209A2 Substituted quinazolin-4-ylamine analogues as modulators of capsaicin
07/31/2003WO2003062205A1 7-sulfonyl-3-benzazepine derivatives as modulators of the dopamine receptor and their use for the treatment of cns disorders
07/31/2003WO2003062203A1 Method
07/31/2003WO2003061687A1 High-concentration preparation of soluble thrombomodulin
07/31/2003WO2003061672A1 Method of treatment of gastrointestinal disease and polymeric composition for use therein
07/31/2003WO2003061671A1 Amido macrolides
07/31/2003WO2003061669A1 Use of alkylphosphocholines for the preventative treatment of protozoan diseases
07/31/2003WO2003061667A1 Pharmaceutically acceptable phosphate-glycerol carrying bodies
07/31/2003WO2003061666A1 Phospholipid bodies and use thereof in the treatment of inflammatory and autoimmune diseases
07/31/2003WO2003061657A1 5-ht3 receptor antagonists and methods of use
07/31/2003WO2003061648A1 Use of cholinesterase antagonists to treat insulin resistance
07/31/2003WO2003061646A1 Process for producing granules containing branched amino acids
07/31/2003WO2003061634A1 Sustained release pharmaceutical composition
07/31/2003WO2003061620A2 Peptide-carrying bodies for immune response
07/31/2003WO2003061587A2 USE OF TGF-β ANTAGONISTS TO TREAT OR TO PREVENT CHRONIC TRANSPLANT REJECTION
07/31/2003WO2003061584A2 Novel substituted benzimidazole dosage forms and method of using same
07/31/2003WO2003061564A2 Gene expression profiles in liver disease
07/31/2003WO2003061563A2 Method of preparing delta-9 tetrahydrocannabinol
07/31/2003WO2003061553A2 An extract of acanthopanax koreanum for the treatment or prevention of hepatitis or the liver protective drug
07/31/2003WO2003057698A3 Spiroazacyclic compounds as monoamine receptor modulators
07/31/2003WO2003051345A3 Use of digestive enzyme mixtures for treating pathological bacterial overgrowth of the small intestine of mammals and humans
07/31/2003WO2003047516A3 Pyrimidine compounds
07/31/2003WO2003045978A3 Antagonist anti-cd40 monoclonal antibody therapy for multiple sclerosis treatment
07/31/2003WO2003041649A3 Cyanoalkylamino derivatives as protease inhibitors
07/31/2003WO2003020702A9 Phosphodiesterase activity and regulation of phosphodiesterase 1-b-mediated signaling in brain
07/31/2003WO2003006016A3 Use of nk-1 receptor antagonists with pyridinic structure, for the treatment of brain, spinal or nerve injury
07/31/2003WO2003000024A3 Uses of dc-sign and dc-signr for inhibiting hepatitis c virus infection
07/31/2003WO2002094202B1 Methods for protecting allogeneic islet transplant using soluble ctla4 mutant molecules
07/31/2003WO2002091850A8 Method for producing a nutrition additive, an additive and its use
07/31/2003WO2002068421A3 Tricyclic compounds and their analogs as inhibitors of cytokine signaling
07/31/2003WO2002062762A3 Potassium channel openers
07/31/2003WO2002060875A8 Nicotinamide biaryl derivatives useful as inhibitors of pde4 isozymes
07/31/2003WO2002058716A3 Treatment of inflammatory bowel disease using growth factors
07/31/2003WO2002030863A3 Ether compounds and compositions for cholesterol management and related uses
07/31/2003WO2002029038A3 Novel proteins and nucleic acids encoding same and antibodies directed against these proteins
07/31/2003WO2002012286A3 Stress proteins and peptides and methods of use thereof
07/31/2003WO2001034566A3 Protease inhibitors
07/31/2003US20030144529 Treating p38 kinase mediated disorders. Compounds of particular interest are defined by Formula I Mitogen-activated protein kinases (MAP) is a family of proline- directed serine/threonine kinases that activate their
07/31/2003US20030144510 Preparation of pharmaceutical salts
07/31/2003US20030144347 Method for treating autoimmune disease
07/31/2003US20030144337 Pyrazole-derived kinase inhibitors and uses thereof
07/31/2003US20030144334 Cyclopentabenzofuran derivatives and their use
07/31/2003US20030144332 Diarylcycloalkyl derivatives, processes for their preparation and their use s pharmaceuticals
07/31/2003US20030144328 Compounds which inhibit leukocyte adhesion mediated by VLA-4
07/31/2003US20030144326 Cyclic amine phenyl beta-3 adrenergic receptor agonists
07/31/2003US20030144323 Phenylalkynes
07/31/2003US20030144311 Propanoic acid derivatives as intergrin receptor antagonists
07/31/2003US20030144309 Inhibitors of Src and other protein kinases
07/31/2003US20030144306 A liquid oral composition comprising a proton pump inhibitor, e,g, omeprazole, lansoprazole,and a buffer; can also contain a parietal cell activator; acid resistance; side effect reduction; kits; drug delivery; Zollinger-Ellison syndrome
07/31/2003US20030144303 Aminopyrimidine and aminopyridine anti-inflammation agents
07/31/2003US20030144302 Process for making substituted pyrazoles
07/31/2003US20030144300 Pyrimidine carboxamides useful as inhibitors of pde4 isozymes
07/31/2003US20030144293 N-alkyl-adamantyl triazinyl benzamide derivatives
07/31/2003US20030144291 Substituted indan derivatives
07/31/2003US20030144290 Substituted 2-cyclohexyl-4-phenyl-1H-imidazole derivatives
07/31/2003US20030144286 Nitrogen compounds such as 3-nitro-N-(1H-benzoimidazol-2-yl)-benzamide, used as nonsteroidal antiinflammatory agents, immunology or interleukin receptor associated kinase (IRAK) modulators; rheumatic diseases; multiple sclerosis
07/31/2003US20030144283 Amide substituted imidazoquinolines
07/31/2003US20030144281 Substituted benzimidazole compounds
07/31/2003US20030144280 Heterocyclic imines, used as cyclooxygenase inhibitors, administered as inflammatory and pain relievers in disorders such as arthritis, neurodegeneration or cancer in mammals
07/31/2003US20030144279 5-Heterocyclo-pyrazoles
07/31/2003US20030144276 Heterocycle-containing carboxylic acid derivative and drug containing the same
07/31/2003US20030144274 Preferential enzyme inhibitors such as 3-(4-Methoxyphenyl)-prop-1-ynyl)-N-(4-carboxybenzyl)benzamide, used for prophylaxis of degenerative diseases including cancer and arthritis
07/31/2003US20030144270 Neurokinin receptor antagonists comprising heterocyclic amides used as antiemetics, antidepressants and/or antitussive agents
07/31/2003US20030144267 Novel compounds
07/31/2003US20030144239 Expression system
07/31/2003US20030144232 Expression system
07/31/2003US20030144214 Alkyl amino acid derivatives useful as pharmaceutical agents
07/31/2003US20030144203 Methods for slowing senescence and treating and preventing diseases associated with senescence
07/31/2003US20030144187 Comprising an osteoprotegerin polypeptide and an immunoglobulin FC region; treatment of bone disorders
07/31/2003US20030143676 Receptor polypeptides and polynucleotides encoding such polypeptides; for treating a disorder characterized by an elevated level of osteopontin
07/31/2003US20030143626 Such as cyclin-dependent kinases and/or bax genes/proteins covalently linked to platform compound (thioredoxin); drug screening
07/31/2003US20030143589 Drug metabolizing enzymes
07/31/2003US20030143285 For therapy andprophylaxis of disease-like conditions caused by extreme body fluid discharge
07/31/2003US20030143284 Food product comprising a high level of natural anti-secretory protein
07/31/2003US20030143271 For therapy and prophylaxis of cyclooxygenase-2 mediated disorder and for providing cardioprotection
07/31/2003US20030143260 Administering to the cow salt of ester of methionine, an ester of methionine amide, and an ester of the hydroxy analogue of methionine
07/31/2003US20030143246 Ganoderma lucidum spores for treatment of autoimmune diseases
07/31/2003US20030143234 For therapy of microbial organism infection
1 ... 862 863 864 865 866 867 868 869 870 871 872 873 874 875 876 877 878 879 880 881 882 ... 1258